Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Century Therapeutics Inc.

    NASDAQ: IPSC · Real-Time Price · USD
    0.58
    -0.00 (-0.51%)
    At close: Jun 17, 2025, 10:22 AM

    Century Therapeutics Statistics

    Share Statistics

    Century Therapeutics has 86.16M shares outstanding. The number of shares has increased by 1.83% in one year.

    Shares Outstanding

    n/a
    		 86.16M

    Shares Change (YoY)

    n/a
    		 1.83%

    Shares Change (QoQ)

    n/a
    		 1.19%

    Owned by Institutions (%)

    n/a
    		 42.97%

    Shares Floating

    n/a
    		 40.6M

    Failed to Deliver (FTD) Shares

    n/a
    		 5,424

    FTD / Avg. Volume

    n/a
    		 0.73%

    Short Selling Information

    The latest short interest is 2.41M, so 2.8% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.41M

    Short % of Shares Out

    n/a
    		 2.8%

    Short % of Float

    n/a
    		 4.17%

    Short Ratio (days to cover)

    n/a
    		 2.84

    Valuation Ratios

    The PE ratio is -0.63 and the forward PE ratio is -0.42. Century Therapeutics's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.63

    Forward PE

    n/a
    		 -0.42

    PS Ratio

    n/a
    		 12.06

    Forward PS

    n/a
    		 133.6

    PB Ratio

    n/a
    		 0.49

    P/FCF Ratio

    n/a
    		 -0.72

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Century Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.5, with a Debt / Equity ratio of 0.33.

    Current Ratio

    n/a
    		 1.5

    Quick Ratio

    n/a
    		 1.5

    Debt / Equity

    n/a
    		 0.33

    Debt / EBITDA

    n/a
    		 -0.48

    Debt / FCF

    n/a
    		 -0.49

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $47,064.29

    Profits Per Employee

    n/a
    		 $-904,042.86

    Employee Count

    n/a
    		 140

    Asset Turnover

    n/a
    		 0.02

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 1.79M

    Effective Tax Rate

    n/a
    		 -1.43%

    Stock Price Statistics

    The stock price has increased by -81.59% in the last 52 weeks. The beta is 1.77, so Century Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.77

    52-Week Price Change

    n/a
    		 -81.59%

    50-Day Moving Average

    n/a
    		 0.53

    200-Day Moving Average

    n/a
    		 0.99

    Relative Strength Index (RSI)

    n/a
    		 52.84

    Average Volume (20 Days)

    n/a
    		 738,690

    Income Statement

    In the last 12 months, Century Therapeutics had revenue of 6.59M and earned -126.57M in profits. Earnings per share was -1.61.

    Revenue

    n/a
    		 6.59M

    Gross Profit

    n/a
    		 6.59M

    Operating Income

    n/a
    		 -138.14M

    Net Income

    n/a
    		 -126.57M

    EBITDA

    n/a
    		 -111.47M

    EBIT

    n/a
    		 -124.78M

    Earnings Per Share (EPS)

    n/a
    		 -1.61
    Full Income Statement

    Balance Sheet

    The company has 58.44M in cash and 53.83M in debt, giving a net cash position of 4.61M.

    Cash & Cash Equivalents

    n/a
    		 58.44M

    Total Debt

    n/a
    		 53.83M

    Net Cash

    n/a
    		 4.61M

    Retained Earnings

    n/a
    		 -782.34M

    Total Assets

    n/a
    		 315.61M

    Working Capital

    n/a
    		 155.13M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -110.14M and capital expenditures -154K, giving a free cash flow of -110.29M.

    Operating Cash Flow

    n/a
    		 -110.14M

    Capital Expenditures

    n/a
    		 -154K

    Free Cash Flow

    n/a
    		 -110.29M

    FCF Per Share

    n/a
    		 -1.4
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -2096.48% and -1920.87%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -2096.48%

    Pretax Margin

    n/a
    		 -1893.7%

    Profit Margin

    n/a
    		 -1920.87%

    EBITDA Margin

    n/a
    		 -1691.79%

    EBIT Margin

    n/a
    		 -2096.48%

    FCF Margin

    n/a
    		 -1673.84%

    Dividends & Yields

    IPSC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for IPSC is $2, which is 244.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $2

    Price Target Difference

    n/a
    		 244.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.03

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist